Chapter title |
Cirrhosis Associated with Pyridoxal 5'-Phosphate Treatment of Pyridoxamine 5'-Phosphate Oxidase Deficiency.
|
---|---|
Chapter number | 338 |
Book title |
JIMD Reports, Volume 17
|
Published in |
JIMD Reports, September 2014
|
DOI | 10.1007/8904_2014_338 |
Pubmed ID | |
Book ISBNs |
978-3-66-244577-8, 978-3-66-244578-5, 978-3-66-244577-8, 978-3-66-244578-5
|
Authors |
Annapurna Sudarsanam, Harry Singh, Bridget Wilcken, Michael Stormon, Susan Arbuckle, Bernhard Schmitt, Peter Clayton, John Earl, Richard Webster, Sudarsanam, Annapurna, Singh, Harry, Wilcken, Bridget, Stormon, Michael, Arbuckle, Susan, Schmitt, Bernhard, Clayton, Peter, Earl, John, Webster, Richard |
Abstract |
We report the case of an 8-year-old boy with pyridoxamine 5'-phosphate oxidase (PNPO) deficiency. He developed seizures at 24 h of age that were refractory to standard anticonvulsant therapy and a trial of pyridoxine but responded to pyridoxal phosphate (PLP) at 28 days of life. Genetic testing identified compound heterozygous mutations in the PNPO gene. Management of encephalopathic episodes required escalation of PLP dose to 100 mg/kg/day by 2 years of age. Routine blood tests at this time showed significantly deranged liver function tests (LFTs). A wedge liver biopsy showed early cirrhosis with marked elevation of pyridoxal and pyridoxic acid levels in the liver sample. Despite extensive investigation, no cause other than PLP therapy could be identified for the cirrhosis. The PLP dose was weaned to 50 mg/kg/day before episodes of encephalopathy recurred. Concurrent with the reduction of his PLP dose, LFTs showed improvement. However, at 8 years of age, there is persistent evidence of hepatic fibrosis and early portal hypertension. We hypothesise that hepatic toxicity due to PLP or its degradation products is the cause of cirrhosis in this boy. Until further evidence becomes available, we would suggest that people with PNPO deficiency are treated with the minimum dose of PLP required to prevent episodes of encephalopathy. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 19 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 32% |
Other | 4 | 21% |
Student > Ph. D. Student | 2 | 11% |
Student > Doctoral Student | 1 | 5% |
Unspecified | 1 | 5% |
Other | 2 | 11% |
Unknown | 3 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 5 | 26% |
Medicine and Dentistry | 4 | 21% |
Agricultural and Biological Sciences | 3 | 16% |
Unspecified | 1 | 5% |
Neuroscience | 1 | 5% |
Other | 1 | 5% |
Unknown | 4 | 21% |